Premium
P4‐051: INFLUENCE OF RIVASTIGMINE TRANSDERMAL ON ACETYLCHOLINE LEVELS IN PATIENTS WITH ALZHEIMER'S DISEASE
Author(s) -
Pardi Paulo Celso
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1566
Subject(s) - rivastigmine , medicine , neurocognitive , dementia , transdermal , disease , pharmacology , psychiatry , cognition , donepezil
Background: Alzheimer’s disease is the cause of dementia that has aroused more interest and concern for overall health worldwide. It is estimated that Alzheimer’s disease affects 10% of people over 65 years of age and over 50% of the elderly populations residing in support homes and /or counterparts in Brazil, therefore our goal has been to evaluate the biological activity and its correlation neurocognitive after administration of rivastigmine in oral and transdermal forms in the search for correlations of pharmacological effects. Methods:A total of 40 individuals of both gender with mildto moderate-stage AD, diagnosed at the beginning of the trial, were studied. Patients were grouped according to type of rivastigmine tartrate treatment where 20 patients were assigned to the oral group (OG) and 20 patients to the patch group (PG). Subsequently, neurocognitive surveys and biological blood analyses were performed over a period of 180 days. ACh were analyzed according to the antiboy receptor The study was approved of the UNIBAN BRASIL (protocol no. 292/08). Results: The rivastigmine tartrate presented between day 0 and day 180, results from the mini-mental state examination of 27.1 + 12.3 for the oral group, and 29.3 + 18.0 for the patch group and in relation to neuropsychiatric inventory an average of 14.1 + 7.0 for the oral group and 16.2 + 6.8 for patch group, since the serum levels of acetylcholine by the identification of antibodies showed a significant difference after 90 days of treatment with tartrate rivastigimina regarding patch shape, presenting a significant change with p <0.04, in relation to 180 days, also showed significant treatment with a change with a p <0.005 compared to day zero. Conclusions: The rivastigmine tartrate presented between day 0 and day 180, results from the minimental state examination of 27.1 + 12.3 for the oral group, and 29.3 + 18.0 for the patch group and in relation to neuropsychiatric inventory an average of 14.1 + 7.0 for the oral group and 16.2 + 6.8 for patch group, since the serum levels of acetylcholine by the identification of antibodies showed a significant difference after 90 days of treatment with tartrate rivastigimina regarding patch shape, presenting a significant change with p<0.04, in relation to 180 days, also showed significant treatment with a change with a p <0.005 compared to day zero.